New role of antinutritional factors, phytic acid and catechin in the treatment of CCl4 intoxication.
Both phytic acid (PA) and catechin (CA) are well known antioxidants of natural origin. They were frequently tried on experimental level as hepatoprotectants, relying only on their antioxidant properties. The present study was conducted mainly to outline the other biochemical pathways underlying the hepatotherapeutic potential of both drugs and to check a possible synergistic action if prescribed concomitantly. As both materials are frequently taken on a daily basis in food and drinks, it will be helpful to pursue their possible utility and/or to check if their value is really of medical importance. For this purpose, CCl(4) was used as a hepatotoxin, we evaluated plasma total sialic acid (TSA), serum ascorbic acid (AA) levels, liver tissue thiobarbituric acid reactive species (TBARS) as a marker for lipid peroxidation and total protein (TP) content as a rough marker to measure hepatic synthetic capability in 80 male Wistar rats as experimental models. Animals were classified into 8 groups (10 rats each), the first as control, the second as PA treated (0.3 mg kg (-1)), orally, the third as CA treated (30 mg kg (-1)) intraperitoneally, the fourth given both drugs, as a single daily dose for 2 weeks. The same design was repeated 24 hours after CCl(4)-intoxication (1mL kg (-1)), intraperitoneally, as a single dose. The results revealed that both PA and CA when used individually, significantly down-regulated TSA in both physiologic (no CCl(4 )treatment) and pathologic (CCl(4)- intoxication) states accompanied by significant decrease in lipoperoxidation. The therapeutic action against TSA and the antioxidant power were abolished by co-administration of both drugs . AA was only decreased by PA and the combination in the physiologic state. Both PA and CA showed significant therapeutic effect for protein synthesis against CCl(4)-intoxication, but the combination abolished this effect. We conclude that both drugs can be considered as a chemotherapeutic against hepatopathies and we for the first time contraindicate the concomitant use of both drugs.
Abdel-Hamid
N M
NM
Department of Biochemistry, College of Pharmacy, Minia University, Egypt. nabilmohie@yahoo.com
Faddah
L M
LM
Al-Rehany
M A
MA
Ali
A H
AH
Bakeet
A A
AA
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000097:blood; D002251:Carbon Tetrachloride / Q000633:toxicity*; D002392:Catechin / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury; D008099:Liver / Q000378:metabolism; D008107:Liver Diseases / Q000097:blood / Q000188:drug therapy*; D008297:Male; D019158:N-Acetylneuraminic Acid / Q000097:blood; D010833:Phytic Acid / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis*
D000975:Antioxidants; D017392:Thiobarbituric Acid Reactive Substances; D010833:Phytic Acid; D002392:Catechin; D002251:Carbon Tetrachloride; D019158:N-Acetylneuraminic Acid; D001205:Ascorbic Acid